Eton Pharmaceuticals, Inc. SEC filings ETON

Eton Pharmaceuticals, Inc. has 421 filings in SEC EDGAR's recent list, going back to Jun 28, 2017. Its latest annual report, Form 10-K, was filed on Mar 19, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Eton Pharmaceuticals, Inc. SEC filings
Form Description Filed Period
S-8 Employee stock plan registration Mar 6, 2026 —
S-8 Employee stock plan registration Nov 19, 2025 —
424B5 Prospectus supplement Dec 12, 2024 —
S-8 Employee stock plan registration Mar 26, 2024 —
S-3 Shelf registration Apr 7, 2023 —
S-8 Employee stock plan registration Mar 21, 2023 —
424B3 Prospectus Apr 9, 2021 —
424B3 Prospectus Apr 7, 2021 —
424B5 Prospectus supplement Oct 15, 2020 —
424B5 Prospectus supplement Oct 13, 2020 —
S-3 Shelf registration Jul 31, 2020 —
424B5 Prospectus supplement Mar 30, 2020 —
S-3 Shelf registration Dec 2, 2019 —
S-8 Employee stock plan registration Mar 28, 2019 —
S-8 Employee stock plan registration Nov 20, 2018 —
424B4 Prospectus Nov 13, 2018 —
S-1/A Amended registration statement Nov 5, 2018 —
S-1/A Amended registration statement Oct 31, 2018 —
S-1/A Amended registration statement Oct 18, 2018 —
FWP Free writing prospectus Sep 28, 2018 —
S-1/A Amended registration statement Sep 25, 2018 —
S-1 Registration statement Aug 10, 2018 —

Showing 22 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ETON (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Deer Park, IL
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1710340

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.